|1.||Stewart, W C: 10 articles (11/2008 - 06/2000)|
|2.||Day, D G: 7 articles (01/2005 - 06/2000)|
|3.||Vidal-Sanz, Manuel: 6 articles (01/2014 - 02/2002)|
|4.||Hollander, David A: 6 articles (05/2012 - 05/2008)|
|5.||Katz, L Jay: 6 articles (05/2012 - 04/2002)|
|6.||Stewart, J A: 6 articles (01/2005 - 06/2000)|
|7.||Cantor, Louis B: 5 articles (07/2009 - 06/2002)|
|8.||Stewart, William C: 5 articles (04/2005 - 06/2002)|
|9.||Sharpe, E D: 5 articles (01/2005 - 06/2000)|
|10.||Holmes, K T: 5 articles (06/2001 - 06/2000)|
10/01/2011 - "Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication that is widely used in glaucoma treatment. "
12/01/2005 - "Although brimonidine is effective in lowering IOP in children, alternative glaucoma therapy should be considered especially in children weighing <20 kg and those younger than 6 years."
04/01/2000 - "This study indicates that 0.2% brimonidine acutely associated with beta-blockers is an interesting new combination treatment useful in the management of glaucoma."
12/01/2005 - "To investigate brimonidine-related side effects and the efficacy of brimonidine in lowering intraocular pressure (IOP) in children with primary infantile and secondary glaucoma. "
12/01/2003 - "Glaucoma patients exhibit improved CS on initiation of brimonidine therapy."
|2.||Ocular Hypertension (Glaucoma, Suspect)
06/01/2014 - "The effects of brimonidine on daytime and nighttime intraocular pressure (IOP) and aqueous humor dynamics were evaluated in volunteers with ocular hypertension (OHT). "
06/01/2014 - "Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension."
03/01/2006 - "[Ocular hypertension in children treated with brimonidine 0.2%. "
11/01/2001 - "To examine the neuroprotective effect of the alpha(2)-adrenergic agonist brimonidine in a chronic ocular hypertension model. "
12/01/1998 - "Eighteen patients with ocular hypertension were enrolled in a prospective, randomized, double-masked study in which 0.2% brimonidine tartrate, administered twice daily, was compared with its vehicle in a crossover fashion. "
|3.||Open-Angle Glaucoma (Glaucoma, Open Angle)
09/01/2001 - "The purpose of this study was to report the acute and chronic effects of brimonidine 0.2% on intraocular pressure (IOP) and pulsatile ocular blood flow (pOBF) in patients with primary open-angle glaucoma (POAG). "
01/01/2015 - "A 78-year-old male with a history of primary open angle glaucoma presented with symptoms of unilateral blurry vision, irritation, and redness shortly after starting brimonidine exclusively in the right eye. "
04/01/2011 - "Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma."
04/01/2004 - "To compare the efficacy and safety of unoprostone versus brimonidine both given twice daily in ocular hypertensive or primary open-angle glaucoma subjects. "
12/01/2003 - "Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients."
09/01/2015 - "Brimonidine gel is a highly selective α2-adrenergic receptor agonist with potent vasoconstrictive effects, which leads to significant reduction of persistent facial erythema in the majority of patients when applied once daily. "
08/01/2015 - "A detailed analysis of adverse events is needed to accurately define worsening erythema and the adverse-events profile associated with brimonidine gel treatment. "
01/01/2015 - "For example, real-world use has shown that a percentage of patients (in our experience, approximately 10 to 20%) treated with brimonidine experience a worsening of erythema that has been called "rebound." Our routine use of this agent for >1 year has yielded strategies to set patient expectations, optimize treatment initiation, and minimize potential problems; this article details those strategies. "
05/01/2014 - "Brimonidine, which was US FDA approved last year and recently sanctioned by Health Canada, has filled an essential therapeutic void in the targeted treatment of diffuse facial erythema. "
05/01/2014 - "Brimonidine effective but may lead to significant rebound erythema."
|5.||Rosacea (Acne Rosacea)
07/01/2014 - "Few studies have looked at the effectiveness of the novel treatment, brimonidine topical gel 0.33%, trademark name Mirvaso®, in the treatment of rosacea. "
09/30/2015 - "Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. "
01/01/2015 - "The role of brimonidine tartrate gel in the treatment of rosacea."
01/01/2015 - "The first available pharmacologic treatment to address the redness associated with rosacea is topical brimonidine. "
01/01/2015 - "Optimizing the use of topical brimonidine in rosacea management: panel recommendations."
|6.||Adrenergic Agonists (Adrenergic Receptor Agonist)
|10.||Adrenergic alpha-Agonists (Adrenergic alpha-Agonist)
|4.||Ambulatory Surgical Procedures (Outpatient Surgery)
|5.||Laser In Situ Keratomileusis (LASIK)